LENZ Therapeutics (LENZ) – Investment Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of LENZ Therapeutics (NASDAQ: LENZ) in the last few weeks:

• 8/25/2026 – LENZ Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/13/2026 – LENZ Therapeutics was upgraded by Zacks Research from “strong sell” to “hold”.
• 8/12/2026 – LENZ Therapeutics had its price target lowered by Piper Sandler from $12.00 to $7.00. They now have a “neutral” rating on the stock.
• 8/12/2026 – LENZ Therapeutics had its “buy” rating reaffirmed by Citigroup Inc..
• 8/11/2026 – LENZ Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 7/15/2026 – LENZ Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/7/2026 – LENZ Therapeutics had its “buy” rating reaffirmed by HC Wainwright.

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.